Eastern Cooperative Oncology Group

Augmedix Announces New Positive Data and Enhancements to Its Ambient AI Product, Augmedix Go

Retrieved on: 
Tuesday, March 12, 2024
Documentation, ECOG, Disease, Patient, SAN, Eastern Cooperative Oncology Group, NLP, Assessment and plan, Oncology, Ambulatory care, Electronic health record, A&P, Heart, HPI, Assessment, Collection

SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced new positive data and product enhancements for Augmedix Go , its ambient AI medical documentation product.

Key Points: 
  • SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced new positive data and product enhancements for Augmedix Go , its ambient AI medical documentation product.
  • Now supporting over 50 medical specialties, the Augmedix Go mobile app optimizes ambient AI technology to produce comprehensive draft medical notes in real time by processing the natural conversations between clinicians and patients.
  • Additionally, 94% of clinicians surveyed reported that Augmedix Go helps them better focus on their patients.
  • By utilizing multiple models that cross-check each other, Augmedix is delivering high quality notes that instill trust among clinicians.

New Post Hoc Analysis from MAVORIC Trial Sheds Light on the Burden of Cutaneous T-Cell Lymphoma on Health-Related Quality of Life

Retrieved on: 
Monday, December 11, 2023
Oncology, Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Well, Mycosis fungoides, Organ, Neuropsychological test, CTCL, Cutaneous T-cell lymphoma, Central Statistics Office (India), Disease, Skin, Eastern Cooperative Oncology Group, Modified, Patient, Itch, Bivariate, Lymph, KKI, Neoplasm, Blood, ECOG, Cancer, ANOVA, Erythroderma, Female, Quality of life, Children's Oncology Group, Nursing, Medical imaging

Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical,” said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors.

Key Points: 
  • Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical,” said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors.
  • Bivariate analysis (t-tests and ANOVA) was used to identify demographic and medical history variables that had a relationship with HRQL.
  • LASSO (least absolute shrinkage and selection operator) regression analysis was used to identify factors that may drive poor HRQL.
  • In multivariate analysis, worse HRQL was associated with being younger, female, moderate or severe pruritus and impaired function (as measured by ECOG PS).

Live from ASH 2023 | Results from Chinese Studies of Olverembatinib Presented in Oral Report at the ASH Annual Meeting for the Sixth Consecutive Year, Including Data Showing Promising Efficacy in Patients with TKI-Resistant and/or Intolerant CML-CP

Retrieved on: 
Wednesday, December 13, 2023
Hydroxycarbamide, Research, Intolerance, Dasatinib, HHT, Aes, Incidence, ASH, Risk, NMPA, TKI, Eastern Cooperative Oncology Group, Hematology, Disease, Hospital, Patient, Nilotinib, QOD, Pacific Time Zone, BCR, Pacific Ocean, CHB, Prognosis, Natural product, ECOG, Cancer, CML, Death, R, Hepatitis, Society, Notifiable disease, BAT, HIV disease progression rates, Pharmaceutical industry, Nursing, EFS

This is the sixth consecutive year in which study results on olverembatinib have been selected for Oral Presentations at the ASH Annual Meeting.

Key Points: 
  • This is the sixth consecutive year in which study results on olverembatinib have been selected for Oral Presentations at the ASH Annual Meeting.
  • After reaching EFS, patients in the BAT arm were allowed to cross-over to the olverembatinib arm for continued treatment.
  • Patients: As of October 17, 2023, a total of 144 patients were enrolled, of whom 96 patients received olverembatinib and 48 received BAT.
  • In addition, the olverembatinib arm has shown a higher cumulative response rate and longer duration of responses.

New Post Hoc Analysis from MAVORIC Trial Sheds Light on Burden of Cutaneous T-cell Lymphoma on Health-related Quality of Life

Retrieved on: 
Monday, December 11, 2023
Well, American Society of Hematology, Mycosis fungoides, Organ, Neuropsychological test, CTCL, Cutaneous T-cell lymphoma, Central Statistics Office (India), Disease, Skin, Eastern Cooperative Oncology Group, Modified, Patient, Itch, Bivariate, Lymph, Neoplasm, TSE, Blood, ECOG, Cancer, ANOVA, Erythroderma, Society, Female, Quality of life, Children's Oncology Group, Kyowa Kirin, B-cell lymphoma

PRINCETON, N.J., Dec. 11, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, today announced health-related quality of life (HRQL) findings from a post hoc analysis of the MAVORIC trial in patients with mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). Researchers analyzed baseline data collected prior to initiation of study treatments and found the symptoms of advanced MF/SS affected HRQL across all domains, with poorer HRQL associated with being younger in age, female, having moderate or severe itching, and impaired function as measured by the Eastern Cooperative Oncology Group performance status (ECOG PS).

Key Points: 
  • Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical," said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors.
  • Bivariate analysis (t-tests and ANOVA) was used to identify demographic and medical history variables that had a relationship with HRQL.
  • LASSO (least absolute shrinkage and selection operator) regression analysis was used to identify factors that may drive poor HRQL.
  • Researchers concluded that assessing a patient's disease concerns may help guide treatment goals and therapeutic choice.

Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases

Retrieved on: 
Monday, November 6, 2023
Șaeș, ECHO, Acute myeloid leukemia, Physical examination, Aes, Food, Progression-free survival, ECOG, Wireless ambulatory ECG, Treatment, MD, Eastern Cooperative Oncology Group, PFS, Doctor of Philosophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, HIV disease progression rates, SD, Washington University School of Medicine, Clinical trial, Cardiotoxicity, STS, RECIST, ANN, Safety, Vital signs, Patient, Toxicity, Pharmaceutical industry

HOUSTON, Nov. 6, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced the presentation of preliminary efficacy findings from the Phase 2 portion of the Company's ongoing U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).

Key Points: 
  • Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).
  • We look forward to further data readouts from this trial and understanding the full potential of Annamycin for the treatment of STS lung mets."
  • The other subject maintained SD through 8 cycles prior to progressing ~6.9 months after initiating treatment with Annamycin.
  • Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107) visit clinicaltrials.gov and reference identified NCT04887298.

Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)

Retrieved on: 
Thursday, September 21, 2023
Progression-free survival, Aes, Clinical trial, ECHO, STS, Toxicity, PFS, Physical examination, Acute myeloid leukemia, Eastern Cooperative Oncology Group, Vital signs, HIV disease progression rates, Patient, ECOG, Annual general meeting, Wireless ambulatory ECG, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, Treatment, Food, Safety, Pharmaceutical industry

HOUSTON, Sept. 21, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat cancers and viruses, today announced the completion of enrollment in the Phase 2 portion of the Company's U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107). Subjects who had stable disease at time of study discontinuation will continue to be followed for progression free response and overall survival.

Key Points: 
  • Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).
  • Subjects who had stable disease at time of study discontinuation will continue to be followed for progression free response and overall survival.
  • "The completion of enrollment for our MB107 study marks an important milestone for our STS clinical development program.
  • Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107) visit clinicaltrials.gov and reference identified NCT04887298.

Leal Health Presents Poster Highlighting Impact of Patient ECOG Scores on Oncology Clinical Trial Eligibility

Retrieved on: 
Monday, August 7, 2023
Leal, Prevalence, COVID-19 pandemic in the Democratic Republic of the Congo, Disability, Clinical trial, Cancer, Eastern Cooperative Oncology Group, Biomarker, ASCO, American Society of Clinical Oncology, Patient, Data, ECOG, Poster, Society, Medical imaging, Birth control, RD

NEW YORK, Aug. 7, 2023 /PRNewswire/ -- Leal Health ("Leal" or "the Company"), formerly known as Trialjectory, an AI-powered treatment decision support platform that democratizes patient access to advanced cancer treatments and empowers the pharmaceutical and biotech industry to execute patient-centric clinical trials, announced today that the Company presented a poster at this year's American Society of Clinical Oncology (ASCO) Breakthrough Annual Meeting, showcasing the impact of patients' ECOG scores on solid and non-solid tumor clinical trial eligibility. The poster was presented by Lena Lapidot, Ph.D., RD, Medical Director at Leal Health.

Key Points: 
  • Leal's study evaluated the impact of ECOG scores on solid and non-solid tumor clinical trial eligibility.
  • These profiles include unique factors relevant to clinical trial eligibility, including disease status, stage, biomarkers, treatment history, comorbidities and demographics.
  • To assess the impact of patients' ECOG scores, Leal adjusted the dataset to reflect a better ECOG score per patient while all other parameters remained constant.
  • In a dataset of 5,018 patients, those with higher ECOG scores (2 or 3) were matched to significantly fewer clinical trials, negatively impacting patients' trial options.

Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023

Retrieved on: 
Friday, May 26, 2023
Hyperglycemia, PM, PD, Progression-free survival, DCR, DLT, Cancer, Cervical cancer, Nasopharyngeal carcinoma, Radiation Therapy Oncology Group, Biomarker, Index, Rash, ASCO, Eastern Cooperative Oncology Group, Patient, Pharmacokinetics, ECOG, CR, MTD, NPC, Lymphocyte, Phase, Society, PD-L1, ORR, Pharmaceutical industry

Being among the 22 China studies selected for Poster Discussions this year, the abstract will also be presented in a Poster Discussion session on June 3rd.

Key Points: 
  • Being among the 22 China studies selected for Poster Discussions this year, the abstract will also be presented in a Poster Discussion session on June 3rd.
  • "It is our pleasure to have the latest results from the TORCH-2 study selected for Poster Discussion at ASCO 2023," said Dr. Amily Zhang, Antengene's Chief Medical Officer.
  • The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 monoclonal antibody toripalimab for the treatment of patients with advanced solid tumors.
  • Study patients had advanced solid tumors with a baseline Eastern Cooperative Oncology Group (ECOG) score of 0-1 (the majority scored 1 on the ECOG scale) and a median of 2 lines of therapy (range:0-7).

23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

Retrieved on: 
Friday, April 14, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., PK, Carcinoma, AACR, PD, Neutrophil, Genetics, Half-life, Progression-free survival, Chills, Pharmacokinetics, American Association for Cancer Research, Itch, Children's Oncology Group, Doctor of Philosophy, Hypothyroidism, PFS, Renal cell carcinoma, Eastern Cooperative Oncology Group, Sarcoma, Primary peritoneal carcinoma, MD, Patient, ECOG, Cancer, AM, MSI-H, Toxicity, Therapy, ORR, Safety, Fatigue, Pharmaceutical industry, Vaccine, CD200R1

23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics (PK) and peripheral saturation of the CD200R1 target.

Key Points: 
  • 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics (PK) and peripheral saturation of the CD200R1 target.
  • Based on the Phase 1 data, a dose of 23ME-00610 given at 1400 mg intravenously every 3 weeks was selected for evaluation of anti-tumor activity in the ongoing Phase 2a portion of the Phase 1/2a (Phase 2a) 23ME-00610 study.
  • Among study participants, most experienced at least 1 treatment related adverse event (TRAE); the majority were Grade 1 or 2.
  • A RP2D of 1400 mg 23ME-00610 was selected for evaluation in the Phase 2a portion of the study.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Retrieved on: 
Monday, April 3, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, MSD, Carcinoma, Male, Hepatitis, PS, Diabetes, Journal of Clinical Oncology, DOR, MRK, Pneumonitis, Toxicity, Cohort study, Medicine, Colitis, Eastern Cooperative Oncology Group, Immunotherapy, Nephritis, Merck & Co., Seagen, Breakthrough therapy, Journal, HIV disease progression rates, Patient, ECOG, Brentuximab vedotin, European Society for Medical Oncology, White, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, ORR, Hematopoietic stem cell transplantation, Food, Glycated hemoglobin, Pharmaceutical industry, Vaccine, Merck

Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Key Points: 
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
  • This marks the first time an anti-PD-1 therapy has been approved in combination with an antibody-drug conjugate in the U.S. in these patients.
  • At baseline, 97.5% of patients had metastatic urothelial cancer and 2.5% of patients had locally advanced urothelial cancer.
  • In KEYNOTE-869, the safety of KEYTRUDA in combination with enfortumab vedotin was investigated in patients with locally advanced or metastatic urothelial carcinoma and who are not eligible for cisplatin-based chemotherapy.